Every 10-Q that CervoMed (CRVO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CRVO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CRVO filings page.
CervoMed Inc. is a clinical-stage biotech developing neflamapimod for age‑related brain disorders, including dementia with Lewy bodies (DLB), nonfluent variant primary progressive aphasia, recovery after stroke and ALS. The drug targets p38α to reduce neuroinflammation and synaptic dysfunction.
For the quarter ended June 30, 2026, CervoMed reported a net loss of $6.6 million, and a first‑half 2026 net loss of $14.5 million, reflecting ongoing research and development and general and administrative spending without product revenue after NIA grant funding ended. Research and development expenses were $4.3 million in the quarter and $9.5 million year‑to‑date; general and administrative expenses were $2.4 million and $5.3 million, respectively.
In June 2026 the company completed a private placement and a registered direct offering, raising combined gross proceeds of about $20.5 million. Cash, cash equivalents and marketable securities totaled approximately $24.9 million at June 30, 2026. Management believes this will fund operations and capital needs through the third quarter of 2027 while it pursues a Phase 3 partnership in DLB.
CervoMed Inc. reported a net loss of $7.96M for the quarter ended March 31, 2026, wider than $4.89M a year earlier, as grant revenue from its NIA award dropped to zero and operating expenses rose.
Research and development spending increased to $5.14M, driven by CMC work on neflamapimod and expansion into frontotemporal disorders and recovery-after-stroke programs, while general and administrative costs rose to $2.98M on higher headcount and professional fees.
CervoMed ended the quarter with $12.9M in cash, cash equivalents and marketable securities and an accumulated deficit of $105.7M. Management states there is substantial doubt about the company’s ability to continue as a going concern, as current resources are not expected to fund operations for 12 months without new financing.
CervoMed Inc. filed its Q3 2025 10‑Q, reporting a net loss of $7,726,639 on grant revenue of $322,569. Operating expenses were $8,366,768, including $6,040,442 for research and development and $2,326,326 for general and administrative costs. Other income totaled $317,560.
The company ended the quarter with $27.3 million in cash, cash equivalents, and marketable securities and stated that these resources are insufficient to fund operations for at least twelve months, creating substantial doubt about its ability to continue as a going concern. For the first nine months of 2025, CervoMed reported a net loss of $18,879,077 and used $16,874,264 in operating cash flow, partially offset by $4,588,687 of net proceeds from selling 550,000 shares under its at‑the‑market program. As of November 5, 2025, common shares outstanding were 9,252,719. The NIA grant has delivered $19.5 million to date, with approximately $1.6 million remaining under current awards.
CervoMed (CRVO) 10-Q, Q2-25: The neuro-focused biotech remains pre-commercial and relies on NIA grant income. Q2 grant revenue fell 46% YoY to $1.76 million as RewinD-LB funding winds down, while R&D expense rose 35% to $5.1 million and G&A climbed 30% to $3.3 million. Operating loss therefore more than doubled to $6.6 million; net loss was $6.3 million (-$0.70/sh) versus $2.3 million (-$0.27/sh) a year earlier. For the six-month period, revenue dropped 35% to $3.7 million and net loss widened to $11.2 million.
Cash & cash equivalents were $8.3 million and marketable securities $25.2 million, giving $33.5 million of liquid resources versus $38.9 million at year-end. Operating cash burn reached $10.4 million YTD, partially offset by $4.6 million raised via a May 2025 at-the-market sale of 550k shares. Management believes current funds plus remaining $2.9 million of NIA grant receivables support operations for “at least” 12 months but acknowledges the need for additional capital to advance lead asset neflamapimod beyond ongoing Phase 2 programs. Shares outstanding rose to 9.25 million.